1. Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First-Time-in-Human Study by Combining 19 F-NMR (Nuclear Magnetic Resonance), 1 H-NMR, and High-Resolution Mass Spectrometric Analyses.
- Author
-
Weston DJ, Thomas S, Boyle GW, and Pieren M
- Subjects
- Humans, Tandem Mass Spectrometry methods, Chromatography, High Pressure Liquid methods, Male, Antitubercular Agents pharmacokinetics, Antitubercular Agents urine, Antitubercular Agents metabolism, Metabolomics methods, Adult, Magnetic Resonance Spectroscopy methods
- Abstract
Alpibectir (also known as BVL-GSK098 and GSK3729098) is a new chemical entity (NCE) with a novel mechanism for the treatment of tuberculosis. The disposition of alpibectir was determined in subjects from a first-time-in-human trial after a single oral dose of 40 mg and after 7 days repeat dosing at 30 mg. Here we present a combined approach of
19 F-NMR (nuclear magnetic resonance),1 H-NMR, and high-resolution mass spectrometry (HRMS) to confidently determine the human metabolic fate of alpibectir. Utilizing multiple sites of fluorination in the molecule, it was possible to fractionate human urine and plasma to confidently detect and quantify the metabolite responses using19 F-NMR. Qualitative detection and structural characterization of F-containing NMR fractions were performed using complementary high-resolution ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) analyses to further add confidence to the metabolite responses in these fractions. Subsequent1 H-NMR then provided unequivocal standard-free structural confirmation for key metabolites, which would not be possible with conventional radioactivity detection and LC-MS/MS techniques. Alpibectir was shown to undergo extensive hydrolysis of the central amide moiety, where the resultant N -dealkylated amine and trifluorobutyric acid products were detected initially by unbiased19 F-NMR detection along with major downstream biotransformations to form a carbamoyl glucuronide conjugate and trifluoroacetic acid, respectively. Parallel UHPLC-MS/MS analyses provided confirmatory or additional structural characterization only where relevant. These concerted data allowed for the qualitative metabolic profile and quantitative determination of drug-related material (DRM) in urine and plasma, along with the percentage of dose excreted in urine, to be reported in a comprehensive, efficient, and data-led manner. SIGNIFICANCE STATEMENT: Combining the selectivity of19 F-NMR (nuclear magnetic resonance) for unfractionated samples as first-intent, data-led sample fractionation prior to19 F-NMR and structure-rich1 H-NMR detection, along with the sensitivity of high-resolution ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), a novel alternative for time-efficient detection and quantification of drug-related material (DRM) in human without use of radiolabeled drug is reported. This allowed more complete data rationalization of human metabolism, permitting early risk assessment and progression of the development of antitubercular agent, alpibectir., (Copyright © 2024 by The Author(s).)- Published
- 2024
- Full Text
- View/download PDF